Levodopa-carbidopa intestinal gel (LCIG)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Advanced Idiopathic Parkinson's Disease
Conditions
Advanced Idiopathic Parkinson's Disease
Trial Timeline
Mar 1, 2006 → Apr 1, 2011
NCT ID
NCT00141518About Levodopa-carbidopa intestinal gel (LCIG)
Levodopa-carbidopa intestinal gel (LCIG) is a approved stage product being developed by AbbVie for Advanced Idiopathic Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00141518. Target conditions include Advanced Idiopathic Parkinson's Disease.
What happened to similar drugs?
15 of 20 similar drugs in Advanced Idiopathic Parkinson's Disease were approved
Approved (15) Terminated (1) Active (5)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00660673 | Phase 3 | Completed |
| NCT00141518 | Approved | Completed |
Competing Products
20 competing products in Advanced Idiopathic Parkinson's Disease